Price
No data yet.
Social Signal Score
Revenue
$4.36B-26.08%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Roy W. O. Jakobs
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 66,401
- Beta
- 0.92
- Country
- NL
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.03
Financials
Revenue
$4.36B-26.1%Net Income
$384.00M+3.8%EBITDA
$1.02B+49.4%Free Cash Flow
$219.00M-17.7%EPS (diluted)
$0.40+5.3%Shares Outstanding (diluted)
968.57M-2.4%Operating Expenses
$1.69BCash & Debt
$1.79BReturn of Capital
$389.00MDividend per Share
$0.99Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $17.83B | $895.00M | $0.95 |
| 2024 | $18.02B | $-702.00M | $-0.75 |
| 2023 | $18.17B | $-466.00M | $-0.49 |
| 2022 | $17.83B | $-1.61B | $-1.68 |
| 2021 | $17.16B | $3.32B | $0.67 |
| 2020 | $17.31B | $1.19B | $1.25 |
| 2019 | $17.15B | $1.17B | $1.21 |
| 2018 | $18.12B | $1.09B | $1.11 |
| 2017 | $17.78B | $1.66B | $1.67 |
| 2016 | $24.52B | $1.45B | $1.48 |
| 2015 | $24.24B | $645.00M | $0.66 |
| 2014 | $21.39B | $415.00M | $0.42 |
| 2013 | $23.33B | $1.17B | $1.20 |
| 2012 | $24.79B | $226.00M | $0.23 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PHG's reported EPS growth of 11.5% a year over 13 years.
- EPS in 5 years
- $1.60
- Implied price
- $38.47
- Return from $26.94
- 7.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $19.12 — -29.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 20 | 24 | 28 | 32 |
|---|---|---|---|---|---|
| 1.5% | -9.9% | -5.7% | -2.2% | 0.8% | 3.5% |
| 6.5% | -5.4% | -1.1% | 2.6% | 5.8% | 8.6% |
| 11.5% | -1.0% | 3.5% | 7.4% | 10.7% | 13.7% |
| 16.5% | 3.5% | 8.2% | 12.2% | 15.7% | 18.8% |
| 21.5% | 7.9% | 12.8% | 17.0% | 20.7% | 23.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·6h ago·Neutral
…integrates robotics, AI-enabled automation and smart devices into a single clinical workflow Cambridge, MA, USA and Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received an up to US$33.7 million award under the Advanced Research Projects Agency for Health (ARPA-H, an agency within the U.S. Department of Health and Human Services (HHS)) Autonomous Interventions and Robotics (AIR) program, led by Dr. Ileana Hancu, t…
View source ↗ - Newsglobenewswire.com·1d ago·Positive
Philips prices EU green bond for EUR 650M August 24, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 650 million fixed rate notes due 2034 (the “Notes”) under its European Medium Term Note (EMTN) program. The Notes are the healthcare industry's first EU Green Bond under the new European Green Bond Standard.
View source ↗
Earnings
Tue, Nov 3(in 2 months)
Consensus estimate $0.41 per share
Typical surprise +23.9% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Jul 27$0.57 vs $0.40beat
- Wed, May 6$0.27 vs $0.24beat
- Tue, Feb 10$0.70 vs $0.56beat
- Tue, Nov 4$0.37 vs $0.37beat
- Tue, Jul 29$0.41 vs $0.32beat
- Tue, May 6$0.27 vs $0.14beat
Estimates and results for PHG via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.